FAZA PET IMAGING IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS
NCT03955393 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2020-12-22
Summary
In renal cell carcinoma (RCC) patients, lymph node metastases detection and treatment are the most critical issues in daily clinical decision-making. Indeed, conversely to other oncological settings, a) nodal status imaging, b) sentinel node technique and c) standard lymphadenectomy have been demonstrated inadequate in the staging and management of RCC patients. A novel, accurate, standardized imaging technique is urgently needed in RCC setting to detect macro and micro nodal invasion, to identify those patients who are at higher risk of having nodal metastases, to accurately plan the best management. Recent studies suggested combining 18F-FAZA PET with CT scanning in the detection of cancer-induced hypoxia.The investigators propose to test 18F-FAZA PET-CT in detecting nodal metastases to improve the management of RCC patients.
Conditions
- Renal Cell Carcinoma (RCC)
Interventions
- OTHER
-
18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS
18F-FAZA is a highly selective PET radiotracer of hypoxia, which has been recently developed and tested in several studies (10-14). 18F-FAZA has been demonstrated to be a marker of hypoxia and pathological metabolic patterns which are common to all renal cancers.
Sponsors & Collaborators
-
IRCCS San Raffaele
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-09-30
- Primary Completion
- 2019-04-30
- Completion
- 2019-09-30
Countries
- Italy
Study Locations
More Related Trials
-
Clinical Study of 18F -FAPI-RGD in Renal Tumor
NCT05976607 ·Status: COMPLETED
-
Tumor Metabolism of Lung Cancer in Patients Who Underwent Percutaneous Radiation Measured With F-18-FDG-PET
NCT00180154 ·Status: COMPLETED
-
FAPI PET/CT for Lymph Node Staging in Colorectal Carcinoma
NCT05209750 ·Status: UNKNOWN ·Phase: NA
-
68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients
NCT05432947 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Fapi-pet in Prostate Cancer.
NCT05192694 ·Status: UNKNOWN ·Phase: NA
-
Lymph Node Assessment Using Simultaneous 18F-FDG-PET and MRI
NCT02180308 ·Status: COMPLETED
-
[18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment
NCT01633255 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
18F-FAPI PET/CT in Patients With Various Types of Cancer
NCT05810324 ·Status: UNKNOWN ·Phase: NA
-
Evaluating the Usefulness of 18F-AlF-FAPI PET/ CT in Orbital Neoplasms
NCT06791226 ·Status: RECRUITING ·Phase: NA
-
[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma
NCT06428708 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
[18F] Fluorocholine FCH Positron Emission Tomography (PET)/Computed Tomography (CT) for Detection of Prostate Cancer Lymph Nodes Metastases
NCT00670527 ·Status: UNKNOWN ·Phase: NA
-
Study of 18F-FAPI Applied to Gastrointestinal Cancer
NCT05788874 ·Status: UNKNOWN
-
Imaging Correlates of Renal Cell Carcinoma Biological Features
NCT01665703 ·Status: COMPLETED ·Phase: NA
-
Use of [18]F-FDG on PET/CT as an Alternative Non-invasive Method for Staging of Lung Cancer
NCT02664792 ·Status: COMPLETED ·Phase: NA
-
68Ga-FAPI-RGD PET/CT for Dual Integrin αvβ3 and FAP-targeted Imaging in Patients With Various Types of Cancer and Compared With 18F-FDG
NCT05543317 ·Status: COMPLETED ·Phase: NA
-
Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 Years
NCT03582254 ·Status: UNKNOWN ·Phase: NA
-
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma
NCT03051581 ·Status: UNKNOWN ·Phase: NA
-
Early Versus Late FDG-PET/CT in Bladder Cancer
NCT03065725 ·Status: COMPLETED
-
[18F]FPIA PET/CT Imaging in Patients With Solid Tumours
NCT04717674 ·Status: RECRUITING ·Phase: PHASE2
-
18F-FAPI and 18F-FDG PET/CT in Patients With Various Types of Cancer
NCT05485792 ·Status: UNKNOWN ·Phase: NA
-
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
NCT00775268 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Monocentric Observational Study on the Diagnostic and Prognostic Role of 18F-PSMA PET (PET/CT and PET/MR) in Prostate Cancer
NCT06167629 ·Status: RECRUITING
-
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma
NCT03051542 ·Status: UNKNOWN ·Phase: NA
-
18F-FAPI-RGD PET/CT in Various Tumor Types
NCT06094530 ·Status: RECRUITING
-
18F-Fluorocholine PET/CT in Medullary Thyroid Cancer
NCT03643055 ·Status: UNKNOWN